Collaboration focuses on studies of AZM-152 to enable submission of an Investigational New Drug (IND) application for the prevention of BPD in preterm infants MALVERN, Pa., Nov. 13, 2024 /PRNewswire-PRWeb/ — Azome Therapeutics, an early-stage drug development company, today announced…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.